| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Autoimmune Epilepsy Evaluation Profile, CSF
MessageSendout, Mayo test code: EPC2
Test Code
LAB1238035
Alias/See Also
AMPA-R Ab CBA
Amphiphysin Ab
Anti-Glial Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
CASPR2-IgG
Contactin-Associated Protein-Like-2 (CASPR2)-IgG
CRMP-5-IgG
Dipeptidyl aminopeptidase-like protein 6
DPPX
EPIEC
GABA-B-R Ab CBA
GFAP
Glutamic Acid Decarboxylase (GAD65)
Leucine-Rich Glioma Inactivated Protein-1 IgG
LGI1-IgG
Metabotropic glutamate receptor 1
mGluR1
Neurochondrin Antibody (NCDN-2)
NMDA-R Ab CBA
Phosphodiesterase 10A (PDE10A)
Purkinje Cell Cytoplasmic Ab Type 2
Purkinje Cell Cytoplasmic Ab Type Tr
Seizures
Spells
Tripartite Motif-Containing Protein 46 (TRIM46)
Amphiphysin Ab
Anti-Glial Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
CASPR2-IgG
Contactin-Associated Protein-Like-2 (CASPR2)-IgG
CRMP-5-IgG
Dipeptidyl aminopeptidase-like protein 6
DPPX
EPIEC
GABA-B-R Ab CBA
GFAP
Glutamic Acid Decarboxylase (GAD65)
Leucine-Rich Glioma Inactivated Protein-1 IgG
LGI1-IgG
Metabotropic glutamate receptor 1
mGluR1
Neurochondrin Antibody (NCDN-2)
NMDA-R Ab CBA
Phosphodiesterase 10A (PDE10A)
Purkinje Cell Cytoplasmic Ab Type 2
Purkinje Cell Cytoplasmic Ab Type Tr
Seizures
Spells
Tripartite Motif-Containing Protein 46 (TRIM46)
CPT Codes
86255 x 19, 86341
Preferred Specimen
Collection vial #1, 4 mL CSF
Minimum Volume
2 mL
Other Acceptable Specimens
Any collection vial
Transport Container
Sterile vial
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated (preferred): 28 days
Ambient: 72 hours
Frozen: 28 days
Ambient: 72 hours
Frozen: 28 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, gross lipemia, gross icterus
Methodology
Indirect Immunofluorescence Assay (IFA), Cell Binding Assay (CBA), Western Blot (WB), Immunoblot (IB), Radioimmunoassay (RIA)
Setup Schedule
Monday through Sunday; Reflex tests: Varies
Report Available
8 to 12 days
Reference Range
Included with report
Clinical Significance
Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of fewer than 2 years using spinal fluid specimens
Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Cognitive impairment/encephalopathy
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency) or "multiple sclerosis"
-History of cancer
-Smoking history (20 or more pack-years) or other cancer risk factors
-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without an obvious cause, especially in a patient with a past or family history of cancer
Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
-Psychiatric accompaniments (psychosis, hallucinations)
-Movement disorder (myoclonus, tremor, dyskinesias)
-Headache
-Cognitive impairment/encephalopathy
-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency) or "multiple sclerosis"
-History of cancer
-Smoking history (20 or more pack-years) or other cancer risk factors
-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without an obvious cause, especially in a patient with a past or family history of cancer
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
